Is beta-lactam therapy, until the patient has been afebrile for 48 hours (at least 5 days), sufficient for the treatment of community-acquired pneumonia?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14523624

Enrollment

200

Registered

2006-02-07

Start date

1999-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired pneumonia Respiratory Pneumonia

Interventions

Patients who experience improvement with beta-lactam monotherapy are randomised, on treatment day 2-5, to receive this medication for either 10 days or until he/she has been afebrile for 48 hours (and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with uncomplicated febrile community-acquired pneumonia, with chest X-ray infiltrates, who initially experience improvement with beta-lactam monotherapy

Exclusion criteria

Exclusion criteria: Nursing home resident, hospitalisation during the preceding month, antibiotic treatment for any reason during the preceding week, ongoing antipyretic medication. Inability to make a telephone conversation or to attend to a follow-up visit

Design outcomes

Primary

Measure	Time frame
1. Clinical cure at the four-week-visit 2. Recurrence of pneumonia within one month	—

Secondary

Measure	Time frame
1. Resolution of X-ray infiltrates 2. C-reactive protein-level at the four-week-visit 3. Reported fever, cough and of physical and mental condition at the telephone conversation or at the follow-up visit	—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026